Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
2007

Study on Tuberous Sclerosis Treatment Timing and Drug Effectiveness

Sample size: 72 publication 15 minutes Evidence: moderate

Author Information

Author(s): Michael P Messina, Aubrey Rauktys, Laifong Lee, Sandra L Dabora

Primary Institution: Brigham & Women's Hospital

Hypothesis

Does the timing of treatment with CCI-779 and interferon-gamma affect the severity of kidney lesions in Tsc2+/- mice?

Conclusion

The presence of growing tumors is crucial for effective treatment, and rapamycin is more effective than CCI-779 in reducing tumor growth.

Supporting Evidence

  • Treatment with CCI-779 or CCI-779 plus IFN-γ reduced kidney tumor burden in Tsc2+/- mice.
  • No significant difference was observed between treatment at 6–8 months versus 10–12 months.
  • Rapamycin was found to be more effective than CCI-779 in reducing tumor growth and improving survival.

Takeaway

If you want to treat kidney problems in mice with a disease called Tuberous Sclerosis, it's better to start treatment when the tumors are already growing, and one medicine works better than another.

Methodology

Tsc2+/- mice were treated with CCI-779 or a combination of CCI-779 and IFN-γ at different ages, and kidney disease severity was evaluated using quantitative histopathology.

Potential Biases

Potential bias due to the use of sibling littermates as controls.

Limitations

The study did not include a group treated with single agent IFN-γ, and the treatment duration for IFN-γ was shorter than in previous studies.

Participant Demographics

Tsc2+/- mice, including both male and female subjects.

Statistical Information

P-Value

0.03

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2210-7-14

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication